{"entity":{"id":"idea-lung-never-smoker-disease-its-own-programme","kind":"idea","name":"Treat lung cancer in never-smokers as its own disease, with its own detection programme","aka":[],"tldr":"About one lung cancer in five happens to someone who never smoked, and they are outside every screening programme in the world. The genomes show it is a different disease that grows more slowly, which is exactly the kind of cancer a screening test could catch.","summary":"Sherlock-Lung sequenced 232 lung cancers in never smokers and found three subtypes defined by copy-number structure, none carrying a tobacco mutational signature. The dominant piano subtype has a low mutational burden, long telomeres and slow growth, with driver progenitor cells datable to many years before diagnosis. Hill and Swanton then showed that oncogenic EGFR and KRAS mutations are present in 18 and 53 percent of histologically normal lung tissue, and proposed that fine particulate matter promotes rather than initiates the cancer.\n\nTogether these say that never-smoker lung cancer has a long pre-clinical phase and an identifiable molecular starting point, which are the two properties that make screening work. Nobody screens for it, because eligibility everywhere is written in pack-years. UK and NHS specifics (Targeted Lung Health Check coverage and uptake, NICE positions and Cancer Drugs Fund status, molecular testing turnaround, thoracic surgery and radiotherapy capacity, audit indicators and trial access) are on the UK and NHS page for lung cancer and are not restated here.","asOf":"2026-09-25","links":[],"tags":["lung-evidence"],"related":["idea-prev-clean-air-never-smoker-endpoints","early-detection-roadmap","prevention-roadmap","lung-cancer-evidence-roadmap"],"cancers":["lung-cancer","nsclc","lung-adenocarcinoma","egfr-mutant-nsclc"],"sections":["early-detection","prevention"],"technologies":["low-dose-ct-screening","liquid-biopsy","wes-wgs"],"targets":["egfr","kras"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":["b-early-detection","b-prevention-adoption","b-rare-cancers","b-trial-diversity"],"keyPapers":["paper-zhang-lung-cancer-never-smokers-nat-genet-2021","paper-hill-lung-adenocarcinoma-air-pollutants-nature-2023","paper-uspstf-lung-cancer-screening-jama-2021"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"A detection programme aimed at never-smokers, using a risk model built from family history, ethnicity, particulate exposure, radon and lung disease rather than smoking, plus a blood-based test tuned to the slow-growing subtype, would find never-smoker lung cancer at a curable stage often enough to change mortality in that group.","rationale":"The disease is rising as a proportion of all lung cancer, disproportionately affects women and people of East Asian ancestry, and is enriched for EGFR mutations, which is to say for the tumours with the best treatment options once found. The Sherlock-Lung evolutionary timing argues that there are years of window. The air pollution work supplies both a population to enrich on and a preventive intervention with a measurable cancer endpoint.","test":"Two arms of work. First, a prospective cohort of never-smokers at elevated risk by a non-smoking risk model, with annual low-dose computed tomography and banked plasma, powered on stage distribution at diagnosis against registry controls. Second, a nested evaluation of whether ultradeep plasma sequencing detects the piano-subtype tumours before they are radiologically visible. Five to eight years to a stage-shift answer.","maturity":"preclinical-evidence","actor":"research","cost":"large","horizonYears":10},"route":"/ideas/idea-lung-never-smoker-disease-its-own-programme/","neighbours":{"idea":[{"id":"idea-prev-clean-air-never-smoker-endpoints","kind":"idea","name":"Evaluate clean-air policies using lung cancer in never-smokers","route":"/ideas/idea-prev-clean-air-never-smoker-endpoints/"}],"roadmap":[{"id":"prevention-roadmap","kind":"roadmap","name":"Cancer prevention roadmap: tobacco control and vaccines → biomarker-guided chemoprevention → interception in carriers","route":"/roadmaps/prevention-roadmap/"},{"id":"early-detection-roadmap","kind":"roadmap","name":"Early detection roadmap: organ screening → blood tests for many cancers","route":"/roadmaps/early-detection-roadmap/"},{"id":"lung-cancer-evidence-roadmap","kind":"roadmap","name":"Lung cancer roadmap: from Doll and Hill and the naming of tobacco, through the cytotoxic plateau, computed tomography screening, EGFR and ALK, immunotherapy by PD-L1, the perioperative trials and PACIFIC, to DLL3 in small-cell disease and a 2032 registry watch","route":"/roadmaps/lung-cancer-evidence-roadmap/"}],"cancer":[{"id":"lung-adenocarcinoma","kind":"cancer","name":"Adenocarcinoma of the lung","route":"/cancers/lung-adenocarcinoma/"},{"id":"egfr-mutant-nsclc","kind":"cancer","name":"EGFR-mutated non-small-cell lung cancer","route":"/cancers/egfr-mutant-nsclc/"},{"id":"lung-cancer","kind":"cancer","name":"Lung cancer (all types)","route":"/cancers/lung-cancer/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"early-detection","kind":"section","name":"Early Detection & Screening","route":"/fronts/early-detection/"},{"id":"prevention","kind":"section","name":"Prevention & Risk","route":"/fronts/prevention/"}],"technology":[{"id":"liquid-biopsy","kind":"technology","name":"Liquid biopsy (ctDNA)","route":"/technologies/liquid-biopsy/"},{"id":"low-dose-ct-screening","kind":"technology","name":"Low-dose CT lung screening","route":"/technologies/low-dose-ct-screening/"},{"id":"wes-wgs","kind":"technology","name":"Whole-exome & whole-genome sequencing","route":"/technologies/wes-wgs/"}],"target":[{"id":"egfr","kind":"target","name":"EGFR","route":"/targets/egfr/"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"}],"bottleneck":[{"id":"b-prevention-adoption","kind":"bottleneck","name":"Prevention we already have is not deployed","route":"/bottlenecks/b-prevention-adoption/"},{"id":"b-rare-cancers","kind":"bottleneck","name":"Rare and paediatric cancers without markets","route":"/bottlenecks/b-rare-cancers/"},{"id":"b-early-detection","kind":"bottleneck","name":"The hardest cancers are found late","route":"/bottlenecks/b-early-detection/"},{"id":"b-trial-diversity","kind":"bottleneck","name":"Trials do not represent the people who get cancer","route":"/bottlenecks/b-trial-diversity/"}],"paper":[{"id":"paper-zhang-lung-cancer-never-smokers-nat-genet-2021","kind":"paper","name":"Genomic and evolutionary classification of lung cancer in never smokers","route":"/key-papers/paper-zhang-lung-cancer-never-smokers-nat-genet-2021/"},{"id":"paper-hill-lung-adenocarcinoma-air-pollutants-nature-2023","kind":"paper","name":"Lung adenocarcinoma promotion by air pollutants","route":"/key-papers/paper-hill-lung-adenocarcinoma-air-pollutants-nature-2023/"},{"id":"paper-uspstf-lung-cancer-screening-jama-2021","kind":"paper","name":"Screening for Lung Cancer: US Preventive Services Task Force Recommendation Statement","route":"/key-papers/paper-uspstf-lung-cancer-screening-jama-2021/"}]}}